VERA THERAPEUTICS, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 40.36 USD | -2.34% |
|
-11.70% | +161.44% |
| May. 10 | Wedbush Adjusts Vera Therapeutics' PT to $32 From $34, Keeps Neutral Rating | MT |
| May. 09 | Vera Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 568.5 | 535.2 | 683.4 | 2,260 | - | - |
| Enterprise Value (EV) 1 | 568.5 | 535.2 | 683.4 | 2,554 | 2,260 | 2,260 |
| P/E ratio | -11 x | -5.78 x | -6.84 x | -17.8 x | -17.2 x | -16.6 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - | 66.3 x |
| EV / Revenue | - | - | - | - | - | 66.3 x |
| EV / EBITDA | - | -5.94 x | -6.98 x | -21.3 x | -15.6 x | - |
| EV / FCF | -24 x | -7.91 x | -7.41 x | -23.2 x | -16.8 x | -17.6 x |
| FCF Yield | -4.17% | -12.6% | -13.5% | -4.32% | -5.96% | -5.67% |
| Price to Book | - | 6.99 x | 6.72 x | 7.49 x | 8.8 x | - |
| Nbr of stocks (in thousands) | 21,278 | 27,658 | 44,433 | 54,701 | - | - |
| Reference price 2 | 26.72 | 19.35 | 15.38 | 41.32 | 41.32 | 41.32 |
| Announcement Date | 3/28/22 | 3/28/23 | 3/20/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | 34.11 |
| EBITDA 1 | - | - | -90.06 | -97.93 | -120 | -145 | - |
| EBIT 1 | - | -34.4 | -90.9 | -102 | -125 | -137 | -129.8 |
| Operating Margin | - | - | - | - | - | - | -380.52% |
| Earnings before Tax (EBT) 1 | - | -32.61 | -89.06 | -95.99 | -121.7 | -135.1 | -148.2 |
| Net income 1 | -53.41 | -32.61 | -89.06 | -95.99 | -121.8 | -133.1 | -146 |
| Net margin | - | - | - | - | - | - | -427.94% |
| EPS 2 | -14.40 | -2.430 | -3.350 | -2.250 | -2.328 | -2.409 | -2.493 |
| Free Cash Flow 1 | - | -23.71 | -67.66 | -92.24 | -110.3 | -134.8 | -128.2 |
| FCF margin | - | - | - | - | - | - | -375.75% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 3/19/21 | 3/28/22 | 3/28/23 | 3/20/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA 1 | - | - | -15.16 | -25.4 | -32.98 | -31.76 | -22.94 | - | -25.86 | - | -29 | -31 | -32 | - | - |
| EBIT 1 | -16.58 | -17.02 | -15.06 | -25.24 | -33.58 | -31.26 | -21.97 | -21.76 | -27.03 | -31.11 | -30.46 | -31.67 | -33.05 | -35.53 | -37.15 |
| Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -16.85 | -17.08 | -14.85 | -24.68 | -32.44 | -30.07 | -20.16 | -20.1 | -25.65 | - | -30.22 | -31.56 | -33.12 | -33.2 | -35.23 |
| Net income 1 | -16.85 | -17.08 | -14.85 | -24.68 | -32.44 | -30.07 | -20.16 | -20.1 | -25.66 | -28.38 | -30.22 | -31.56 | -33.12 | -33.2 | -35.23 |
| Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EPS 2 | -0.9700 | -0.7100 | -0.5500 | -0.9100 | -1.190 | -0.8000 | -0.4600 | -0.4500 | -0.5800 | -0.5600 | -0.5715 | -0.5918 | -0.6097 | -0.5933 | -0.6000 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 3/28/22 | 5/16/22 | 8/10/22 | 11/9/22 | 3/28/23 | 5/11/23 | 8/10/23 | 11/9/23 | 3/20/24 | 5/9/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | 293 | - | - |
| Net Cash position 1 | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | -2.444 x | - | - |
| Free Cash Flow 1 | - | -23.7 | -67.7 | -92.2 | -110 | -135 | -128 |
| ROE (net income / shareholders' equity) | - | - | -122% | -107% | -52.6% | -49.2% | - |
| ROA (Net income/ Total Assets) | - | - | -82.8% | -62.5% | -48.5% | -46.5% | - |
| Assets 1 | - | - | 107.6 | 153.5 | 250.9 | 286 | - |
| Book Value Per Share 2 | - | - | 2.770 | 2.290 | 5.520 | 4.700 | - |
| Cash Flow per Share | - | - | - | - | - | - | - |
| Capex 1 | - | - | - | 0.06 | 0.1 | 0.12 | 0.12 |
| Capex / Sales | - | - | - | - | - | - | 0.36% |
| Announcement Date | 3/19/21 | 3/28/22 | 3/28/23 | 3/20/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
41.32
USD
Average target price
56.7
USD
Spread / Average Target
+37.22%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +168.66% | 2.26B | |
| +17.96% | 44.96B | |
| +1.17% | 42.65B | |
| +47.36% | 41.85B | |
| -4.27% | 29.04B | |
| +11.42% | 26.08B | |
| -21.39% | 19.03B | |
| +4.86% | 12.75B | |
| +27.29% | 12.06B | |
| -3.50% | 11.75B |
- Stock Market
- Equities
- VERA Stock
- Financials Vera Therapeutics, Inc.